Show Notes
Recce Pharmaceuticals Ltd managing director and CEO James Graham talked with Proactive about the company’s exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for RECCE® 327 topical gel (R327G) in Australia and New Zealand.
Graham described the agreement as a significant step for Recce Pharmaceuticals, highlighting Arrotex’s pharmaceutical sales, marketing, distribution and market-access capabilities across Australia and New Zealand. He said the partnership allows each company to focus on its respective strengths as R327G progresses through clinical development.
Graham also discussed Arrotex’s reach within Australia’s Pharmaceutical Benefits Scheme and across hospitals, clinics and pharmacies, describing the company as a strong commercialisation partner for R327G.
Graham discussed clinical work underway in Indonesia as well as the company’s Australian Phase 3 study, with Australian data expected to be an important part of the regulatory pathway.
He said the Indonesian study was already demonstrating what he described as a strong efficacy signal while maintaining an excellent safety profile. The Australian study remains underway, with further clinical data expected as the program advances.
Looking ahead, Graham identified potential clinical data readouts, regulatory submissions and additional licensing opportunities in surrounding markets as important milestones for R327G.
Visit Proactive’s YouTube channel for more interviews and updates from listed companies and industry leaders. If you found this video useful, give it a like, subscribe to the channel and enable notifications so you don’t miss future Proactive content.
#ReccePharmaceuticals #RCE #RECEF #R327G #RECCE327 #ArrotexPharmaceuticals #DiabeticFootInfection #DFI #Phase3 #ClinicalTrials #Biotech #Pharmaceuticals #AntiInfectives #DrugDevelopment #Healthcare #ASX #Australia #NewZealand
More from Proactive - Interviews for investors
archTIS CEO and managing director Daniel Lai talked with Proactive about the cybersecurity company's record September quarter, progress toward operating cash flow break-even, ongoing negotiations with the US Department of Defense and the growth opportunities emerging from artificial intelligence.
Carnavale Resources Ltd managing director Humphrey Hale talked with Proactive about the bankable feasibility study (BFS) for the initial open-pit development of the Kookynie Gold Project in Western Australia.
Lightning Minerals managing director and CEO Troy Brice talked with Proactive about the company’s option agreement with Kincora Copper, which provides a funded pathway for exploration of Lightning Minerals’ Lachlan Fold Belt tenements while allowing the company to concentrate on its priority projects.
FireFly Metals Ltd managing director Steve Parsons talked with Proactive about the company’s latest copper-gold discovery at the Mount Joy prospect within the Green Bay Project in Newfoundland, Canada, and the wider regional exploration program underway around the proposed Ming Mine restart.
Resolution Minerals Ltd US operations chief executive Craig Lindsay talked with Proactive about the latest drilling results from the company’s 100%-owned Horse Heaven Project in Idaho, where Golden Gate North has developed into a broad gold-mineralised system extending for at least 500 metres.